<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810524</url>
  </required_header>
  <id_info>
    <org_study_id>SunYat-senU 5010 Hepatitis B</org_study_id>
    <nct_id>NCT00810524</nct_id>
  </id_info>
  <brief_title>Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection</brief_title>
  <official_title>Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Influence of antiviral treatment to the long term prognosis of patients with chronic HBV
      infection. The aim of antiviral treatment for HBV is to reduce the long term severe
      complications. In this study, the investigators divided patients with chronic HBV infection
      into two groups, which start early antiviral treatment and conventional antiviral treatment
      respectively. All the patients will be followed for ten years. From this study, the
      investigators want to find out the optimal time for patients with chronic HBV infection to
      start antiviral treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence rate of hepatic carcinoma</measure>
    <time_frame>10 years after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence rate of liver cirrhosis</measure>
    <time_frame>10 years after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence rate of fulminant hepatitis</measure>
    <time_frame>10 years after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine</intervention_name>
    <description>100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enticavir</intervention_name>
    <description>0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir Dipivoxil Tablets</intervention_name>
    <description>10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HBsAg positive for more than 6 months.

          -  HBeAg positive.

          -  HBV DNA over 10E5 copies/ml.

        Exclusion Criteria:

          -  Previous antiviral treatment for HBV.

          -  Co infection of HIV, HCV, HEV, HAV, or HAV.

          -  Evidence of hepatic carcinoma.

          -  Evidence of autoimmune disease.

          -  Evidence of thyroid disease.

          -  History of mental sickness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gao zhiliang, M. D.</last_name>
    <role>Study Director</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gao zhiliang, M. D.</last_name>
    <phone>+862085252037</phone>
    <email>zhanlianh@21cn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huang zhanlian, M. D.</last_name>
    <phone>+8685252046</phone>
    <email>zhanlianh@21cn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Third Affiliated Hospital Of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gao zhiliang, M. D.</last_name>
      <phone>+862085252037</phone>
      <email>zhanlianh@21cm.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gao zhiliang, M. D.</last_name>
      <phone>+8685252037</phone>
    </contact>
    <investigator>
      <last_name>gao zhiliang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <last_update_submitted>December 17, 2008</last_update_submitted>
  <last_update_submitted_qc>December 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>The Third Affliated Hospital of Sun Yat-sen University</name_title>
    <organization>The Third Affliated Hospital of Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>antiviral treatment</keyword>
  <keyword>long term prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

